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Background: After liver transplantation primary sclerosing cholangitis (PSC), the
condition returns in the transplanted liver in a subset of patients (recurrent primary
sclerosing cholangitis, rPSC).
Aim: To define risk factors for rPSC.
Methods: We searched Pubmed, Embase, Web of Science, and Cochrane library
for articles published until March 2018. Studies addressing risk factors for develop-
ing rPSC were eligible for inclusion. A random effects meta‐analysis was conducted
using hazard ratios (HR) as effect measure. Study quality was evaluated with the
Newcastle Ottawa scale. Statistical analysis was performed using Cochrane Review
Manager.
Results: The electronic database search yielded 449 results. Twenty‐one retrospec-
tive cohort studies met the inclusion criteria for the review; 14 were included in the
meta‐analysis. The final cohort included 2159 patients (age range 31‐49 years,
68.8% male), of whom 17.7% developed rPSC. Colectomy before liver transplanta-
tion, HR 0.65 (95% CI: 0.42‐0.99), cholangiocarcinoma before liver transplantation,
HR 2.42 (95% CI: 1.20‐4.86), inflammatory bowel disease, HR 1.73 (95% CI: 1.17‐
2.54), donor age, HR 1.24 (95% CI 1.0‐1.45) per ten years, MELD score, HR 1.05
(95% CI: 1.02‐1.08) per point and acute cellular rejection, HR of 1.94 (95% CI: 1.32‐
2.83) were associated with the risk of rPSC.
Conclusions: Multiple risk factors for rPSC were identified. Colectomy before liver
transplantation reduced the risk of rPSC.
As part of AP&T’s peer‐review process, a technical check of this meta‐analysis was per-
formed by Dr Y Yuan. The Handling Editor for this article was Professor Peter Hayes, and it
was accepted for publication after full peer‐review.
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1 | INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic fibroinflammatory
disorder of the biliary tree, typified by its strong association with
inflammatory bowel disease (IBD), usually ulcerative colitis.1–3 As to
date, no specific treatment has been shown to attenuate the pro-
gressive course of disease, with orthotopic liver transplantation
(OLT) remaining the only lifesaving therapy.
Unfortunately, PSC recurs after OLT (rPSC) in approximately
20%‐25% of patients over a 10‐year period, imparting significant
morbidity, need for retransplantation and an increased mortality
risk.3–5 The aetiology of rPSC remains largely unknown but identify-
ing possible risk factors may help to develop treatment strategies to
reduce its incidence. rPSC impacts graft and recipient survival and,
with donor livers being scarce, efficient usage is of upmost impor-
tance.6 Previous studies have reported several potentially modifiable
risk factors for rPSC including colectomy, use of extended criteria
donor grafts, choice of primary immunosuppression and cold
ischemic time. However, results were inconsistent between studies.7
In 2006, Gautam et al performed a systematic review aiming to pool
all described risk factors but, due to a lack of adequate information,
they were unable to perform a meta‐analysis.8 In the past decade,
larger cohorts of PSC patients undergoing OLT were analysed to
identify risk factors for rPSC. The current systematic review and
meta‐analysis was conducted to summarise all available data in order
to define risk factors for rPSC.
2 | METHODS
2.1 | Recurrence of PSC
In 1999 Graziadei et al proposed criteria for diagnosing rPSC: the
Mayo Clinic criteria, which now serve as the gold standard for
diagnosing rPSC.9,10 The Mayo Clinic criteria consist of a con-
firmed diagnosis of PSC prior to liver transplantation; cholangiog-
raphy showing intrahepatic and/or extrahepatic biliary stricturing,
beading and irregularity after 90 days after transplantation or liver
biopsy showing fibrous cholangitis and/or fibro‐obliterative lesions
with or without ductopenia, biliary fibrosis or biliary cirrhosis.
Moreover, conditions such as hepatic artery thrombosis/stenosis,
established ductopenic rejection, anastomotic strictures alone, non‐
anastomotic strictures or ischemic type biliary lesions (ITBL) within
90 days and ABO incompatibility between donor and recipient
must be excluded (Table S1).
2.2 | Search strategy
A literature search without any country or language restriction was
performed to identify studies that described risk factors for recurrent
PSC after liver transplantation. The search of the following databases
was performed: Pubmed, Embase, Web of Science, Cochrane library
for studies published until March 2018 using a combination and vari-
ation of the following key words and terms “primary sclerosing
cholangitis” and “recurrence” and “liver transplantation” or “hepatic
transplant” and “risk factor” or “risk.” The inclusion process is
depicted in Figure 1.
2.3 | Study selection
Two authors (ICS and KSK) independently reviewed all found articles
for titles, abstracts and consulted full text when abstracts did not
provide sufficient information about the study. Abstracts were inde-
pendently checked for inclusion.
2.4 | Study inclusion and exclusion
Articles were selected by means of the Preferred Reporting Items
for Systematic Reviews and Meta‐Analyses (PRISMA) statement.11
Studies addressing risk factors for developing rPSC after liver
transplantation were eligible for inclusion in the review. Each study
had to provide information regarding characteristics of patients at
transplantation and describe rPSC as outcome as well as risk fac-
tors for rPSC. Excluded were case series, case studies, reviews and
studies only including children. When studies used overlapping
cohorts from the same institution addressing equivalent risk fac-
tors, the study with the smallest cohort was excluded from the
analysis. Due to the low number of studies regarding risk factors
for rPSC, studies with various criteria for diagnosing rPSC were
included.
2.5 | Risk of bias and quality assessment
Quality of included studies was evaluated by two authors (ICS and
KSK) with the Newcastle Ottawa Scale for cohort studies.12 Studies
were evaluated by selection with a maximum of four stars, compara-
bility with a maximum of two stars and outcome with a maximum of
three stars. Risk of publication bias would be assessed for each risk
factor with funnel plots if more than 10 studies were included in the
meta‐analysis.13
2.6 | Data extraction
Extracted from articles were authors, country of origin, publication
date, study design, number of patients, patient characteristics, recur-
rence in group, number of patients with and without risk factor and
outcome, with corresponding odds ratios (OR), risk ratios, relative
risks, hazard ratios, 95% confidence intervals and p‐values for uni-
variate analysis from tables and describing text. Multivariate analyses
were not included due to lack of data and because different control
factors were used across studies when a multivariate analysis was
performed.
2.7 | Statistical analysis
Through pooled proportion meta‐analysis using a random effects
model, a pooled recurrence rate was calculated. Data regarding risk
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factors: the hazard ratio was used as effect measure in the meta‐
analysis. When recurrence proportions in groups and number of
events were available, hazard ratios could be calculated.14 If such
information was not provided, OR and relative risks were taken as
good estimates of hazard ratios. When studies reported hazard ratios
for different cut‐off points comparing to a reference class, risks were
transformed into continuous scale.15
Statistical analysis was performed using Cochrane Review Man-
ager (Revman 5.3) and R. Hazard ratios were pooled using random‐
effects inverse variance models using 95% confidence intervals.
Pooled risks were further explained with forest plots. Heterogeneity
between studies was measured using I2, assigning categories low,
moderate and high with I2 of respectively 25%, 50% and 75%.16,17
3 | RESULTS
The electronic database search yielded 449 results. All abstracts and
titles were reviewed, and 21 studies were identified that addressed
risk factors for rPSC after liver transplantation. Seven were excluded
due to cohort overlap and addressing the same risk factors as larger
studies of the same cohort.5,18–23 In total, 14 retrospective cohort
studies met the inclusion criteria for the review (Table 1).
Of studies included in the review, suspicion of overlapping
cohorts was found in three studies from the United Kingdom,6,24,25
two studies including patients from Colorado, United States22,26 and
two studies using patient data from Norway.27,28 When studies
using overlapping cohort addressed the same risk factors, the study
with the largest cohort was included in the meta‐analysis per risk
factor.
Twelve of fourteen studies used the Mayo clinic criteria pro-
posed by Graziadei et al for diagnosing rPSC and two studies29,30
described other criteria (Table S2).
In total, 14 studies were included in the meta‐analysis describ-
ing possible risk factors for rPSC for 2481 patients (Table 1). One
study described recipient age as a possible risk factor for rPSC and
used different age cut‐off points instead of age as a continuous
scale. In this particular case, recipient age in this particular case
was changed into a continuous variable.27 To ascertain the recur-
rence rate without overlapping cohorts, we included studies with
the largest number of patients in the cohort, which resulted in a
total cohort of 2159 patients. Of these 2159 patients, with median
age ranging from 31 to 49 years, 1486 were male (68.8%) and 369
developed rPSC. Through a pooled proportion analysis using ran-
dom effects model we found a recurrence rate of 17.66% (95% CI:
14.86‐20.86).
The following risk factors were examined: recipient sex, donor
sex, donor‐recipient sex mismatch, recipient age, donor age, living or
deceased donor, cytomegalovirus (CMV) status of recipient, cholan-
giocarcinoma before liver transplantation, IBD presence (ulcerative
colitis or Crohn's disease not specified), Model of End Stage Liver
Disease (MELD) score at liver transplantation, type of biliary
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anastomosis at liver transplantation, any episode of acute cellular
rejection and primary immunosuppressive regimen.
We found that colectomy before liver transplantation, presence
of IBD, cholangiocarcinoma before liver transplantation, donor age
(per 10 years), any episode of acute cellular rejection after liver
transplantation, multiple episodes of acute cellular rejection and lab-
oratory MELD score per point were associated with the risk of rPSC
(Figure 2).
3.1 | Colectomy before liver transplantation
Eight studies described colectomy before liver transplantation.4,6,24–
27,31,32 Among these studies, two could not be evaluated due to
overlapping cohorts.24,25 Among the six studies left, meta‐analysis
showed a pooled HR of 0.65 (95% CI: 0.42‐0.99), I2 = 0%, which
indicates that colectomy before liver transplantation may reduce the
risk for developing rPSC (Figure 2A).
3.2 | IBD presence
IBD presence (ulcerative colitis and Crohn's disease) was evaluated
in eight studies,3,4,24,26,28,29,32,33 of which two28,29 studies did not
provide enough information to calculate the HR. Among the six
remaining studies, Hildebrand et al found IBD presence to be a
significant risk factor for rPSC with HR of 1.15 (95% CI:
1.15‐4.75).33 Meta‐analysis describing a total cohort of 1079
patients showed a pooled HR of 1.73 (95% CI: 1.17‐2.54),
I2 = 21% (Figure 2B).
3.3 | Cholangiocarcinoma
Six studies described the influence of cholangiocarcinoma on
rPSC.3,6,22,24,26,29 Among these, two had to be excluded due to over-
lapping cohorts.22,24 Meta‐analysis of four remaining studies includ-
ing a total cohort of 1083 patients, showed cholangiocarcinoma to
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CD, Crohn's disease; IBD, inflammatory bowel disease; LT, liver transplantation; N, sample size; NR, not reported; UC, ulcerative colitis.
aStudy was included in the meta‐analysis.
bMean ± standard deviation.
cStudy diagnosed recurrent primary sclerosing cholangitis by other criteria than Mayo Clinic criteria.
dInterquartile range.
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(B) IBD presence
(C) CCA before liver transplantaon
(D) Donor age per ten years
(E) Any episode of ACR 
(F) Mulple episodes of ACR 
(G) MELD scoreper point 
(A) Colectomy before liver transplantaon
F IGURE 2 Potential risk factors for recurrent primary sclerosing cholangitis: (A) Colectomy before liver transplantation (B) IBD
(Inflammatory bowel disease) presence (C) CCA (cholangiocarcinoma) before liver transplantation (D) Donor age per 10 y. (E) Any episode of
ACR (acute cellular rejection) (F) Multiple episodes of ACR (G) MELD (Model of End Stage Liver Disease) score per point
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be a significant risk factor for rPSC with a pooled HR of 2.42 (95%
CI: 1.20‐4.86), I2 = 0% (Figure 2C).
3.4 | Donor age
Donor age was evaluated in five studies.3,6,26,28,33 Hildebrand et al
found an advanced donor age to be a significant risk factor for rPSC
with HR of 1.02 (1.01‐1.04).26,33 Meta‐analysis in a total cohort of
1310 patients showed a pooled HR of 1.24 (95% CI: 1.07‐1.45) per
10 advancing years, I2 = 7% (Figure 2D).
3.5 | Acute cellular rejection
Acute cellular rejection was evaluated in seven studies.3,4,26,28,29,31,32
Meta‐analysis showed a pooled HR of 1.94 (95% CI: 1.32‐2.83),
I2 = 18% (Figure 2E).
3.6 | Multiple episodes of acute cellular rejection
Having multiple episodes of acute cellular rejection was evaluated in
three studies.3,4,33 Meta‐analysis showed a pooled HR of 1.98 (95%
CI: 1.01‐3.86), I2 = 8% (Figure 2F).
3.7 | MELD score
Two studies26,33 were included in the meta‐analysis in which MELD
score was a significant risk factor with a calculated pooled HR of
1.05 (95% CI: 1.02‐1.08), I2 = 0% (Figure 2G).
Recipient or donor sex, donor‐recipient sex mismatch, recipient
age, living or deceased donor, CMV status of recipient, CMV disease,
type of biliary anastomosis and type of primary immunosuppression
were not significantly associated with the risk of developing rPSC.
Corresponding forest plots can be found in the supplemental data
(Figure S1).
The heterogeneity of the studies included in the meta‐analysis
showing significant risk factors was low (I2 = 0%‐22%). Heterogene-
ity of the studies of which we did not find a significant risk factor in
the pooled data analysis was moderate to high (I2 = 0%‐64%).
3.8 | Risk of bias in included studies
None of the analyses per risk factor included more than 10 studies.
These numbers were too low to obtain sufficient power to distin-
guish chance from real asymmetry in funnel plots.13 Therefore, fun-
nel plots were not assessed to calculate risk of bias. The Newcastle
Ottawa Scale was used for quality assessment of the studies; studies
scored 5‐9 points with a median of 8 points. Further details can be
found in the Table S3.
4 | DISCUSSION
PSC is a rare disease associated with considerable morbidity and
mortality. Medical treatment does not improve disease progression
and liver transplantation remains to date the only curative option.34
In the era of donor scarcity, efficient usage of donor livers is essen-
tial. Recurrence of primary disease such as PSC (rPSC) has deleteri-
ous consequences, resulting in frequent endoscopic retrograde
cholangiography or retransplantation in 37.6%‐45.9% of cases.6,27
Therefore, identifying potential risk factors is essential to categorise
and possibly develop interventions to reduce the chances of recur-
rent disease.
The included studies without possible overlapping cohorts
revealed 369 (17.7%) cases of rPSC after liver transplantation. We
found that cholangiocarcinoma before liver transplantation, acute
cellular rejection after transplantation and IBD presence were risk
factors for rPSC. Colectomy before liver transplantation was anal-
ysed in 1465 patients, in which the pooled analysis showed a signifi-
cant risk reduction. Furthermore, the presence of IBD, which occurs
in up to 70% of patients with PSC, was a significant risk factor for
rPSC after liver transplantation.
One theory for the protective nature of performing a colectomy
derives from the strong association between PSC and IBD, suggest-
ing that damage to the biliary tract might result from aberrant
lymphocyte trafficking from the intestinal mucosa to the liver.35 The
association between colectomy and PSC was also investigated in a
recent study by Nordenvall et al, which showed colectomy prior to
PSC diagnosis to be protective against a progressive PSC disease
course, although the study did not inform on disease severity and
colectomy indication.36 A recent study by Trivedi et al revealed a
colectomy with end‐ileostomy to have a more favourable outcome
on graft survival and a protective effect on recurrence of biliary
strictures as opposed to ileal pouch‐anal anastomosis or no
colectomy.37 Moreover Joshi et al identified active IBD as a
significant predictor for graft failure after liver transplantation.38
However, performing a colectomy before transplantation is not
routine practice and a colectomy is usually reserved for IBD patients
with ongoing inflammation and subsequent high‐grade dysplasia
found in biopsies during colonoscopy.39 Based on the current data
we may adopt a lower threshold for colectomy in PSC‐IBD patients
with persistent intestinal inflammation and progressive liver disease
that are likely to need a liver transplantation.
Cholangiocarcinoma has deleterious consequences with a high
mortality rate in a non‐transplant setting up to 80% in 1 year.40
The current meta‐analysis showed pre‐transplant cholangiocarci-
noma to be a significant risk factor for rPSC. Gordon et al
explained this finding by the therapy for cholangiocarcinoma rather
than the cholangiocarcinoma itself. The chemotherapy may induce
changes in the native hepatic artery, resulting in secondary
sclerosing cholangitis after liver transplantation, which makes it
difficult to differentiate from recurrent PSC. However, this finding
is not fully explained by chemotherapy: it is unknown how
many patients in the meta‐analysis received treatment for cholan-
giocarcinoma, especially because cholangiocarcinoma is a contraindi-
cation for liver transplantation in most countries.
Cholangiocarcinoma is often diagnosed in the explant after liver
transplantation.41
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This meta‐analysis also showed acute cellular rejection to be a
risk factor for rPSC. Acute cellular rejection results in injury of biliary
epithelium, which could lead to increased autoimmune epitopes and
therefore immune‐mediated ductal damage.29 It has also been postu-
lated that there might be a predisposition in these patients for rPSC
as well as acute cellular rejection. Others suggest that the treatment
of acute cellular rejection might predispose developing rPSC.4 Cho-
longitas et al found the need for maintenance steroids, for longer
than 3 months after transplantation, to be a significant risk factor for
rPSC.25 Prolonged steroid use is debated to influence the develop-
ment rPSC by altering the immune response but may also reflect
more severe IBD activity.24,42
Higher pre‐transplant laboratory MELD score was a significant
risk factor for developing rPSC. Although only two studies were
included, 612 patients were analysed and found an increased risk for
rPSC per MELD point. MELD score assesses severity of liver disease
to determine priorities in allocating organs for liver transplantation. It
also predicts survival in patients with cirrhosis.43 However, patients
with PSC have a relative low MELD score and can be assigned addi-
tional MELD points when at least two spontaneously septic episodes
occur within 6 months.44 Thus, high MELD scores may reflect ongo-
ing inflammation with corresponding septic episodes in PSC patients,
indicating that a more severe disease course pre‐LT predicts chances
on rPSC post‐LT.
In 2011, Egawa et al identified CMV infection as a potential risk
factor for developing rPSC.3 However, studies included in the meta‐
analysis, which described CMV status, were scarce and the definition
of “CMV infection” was not similarly noted.3,25,26 Therefore, in this
meta‐analysis CMV infection could not be identified as a potential
risk factor (Supplemental data).
A limitation of the current meta‐analysis may be the size of the
included studies. PSC is a rare disease and rPSC occurs in the lesser
proportion of patients after transplantation. Nevertheless, this is the
largest meta‐analysis regarding this topic to date. Another limitation
is the definition of rPSC. Although the criteria for rPSC described by
Graziadei et al9 are the current gold standard, the gold standard was
not used to define rPSC in all studies and it remains challenging to
discriminate between rPSC and other biliary diseases such as ITBL
or (ductopenic) chronic rejection.45 Taking into account the variable
length of studies and the lack of screening methods for rPSC, the
prevalence of rPSC may be higher than stated in the included stud-
ies. Future studies should focus on finding a non‐invasive measure
to discriminate between rPSC and ITBL and until then include the
use of the standardised criteria for diagnosing rPSC as stated by
Graziadei et al.
In conclusion, this meta‐analysis revealed several risk factors for
rPSC. Colectomy before or during liver transplantation is protective
of rPSC and should be considered in the severe diseased, for exam-
ple, high colonic activity. Furthermore, this meta‐analysis showed
cholangiocarcinoma, presence of IBD as well as donor age and acute
cellular rejection to be risk factors for developing rPSC. The associa-
tion between the found risk factors and recurrence of PSC need to
be confirmed in future studies.
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